Pfizer Revenue 2006-2019 | PFE
Pfizer annual/quarterly revenue history and growth rate from 2006 to 2019. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Pfizer revenue for the quarter ending June 30, 2019 was $13.264B, a 1.5% decline year-over-year.
- Pfizer revenue for the twelve months ending June 30, 2019 was $53.657B, a 0.78% increase year-over-year.
- Pfizer annual revenue for 2018 was $53.647B, a 2.1% increase from 2017.
- Pfizer annual revenue for 2017 was $52.546B, a 0.53% decline from 2016.
- Pfizer annual revenue for 2016 was $52.824B, a 8.13% increase from 2015.
Pfizer Annual Revenue
(Millions of US $) |
| 2018 |
$53,647 |
| 2017 |
$52,546 |
| 2016 |
$52,824 |
| 2015 |
$48,851 |
| 2014 |
$49,605 |
| 2013 |
$51,584 |
| 2012 |
$54,657 |
| 2011 |
$61,035 |
| 2010 |
$65,165 |
| 2009 |
$49,269 |
| 2008 |
$48,296 |
| 2007 |
$48,418 |
| 2006 |
$48,371 |
| 2005 |
$47,405 |
Pfizer Quarterly Revenue
(Millions of US $) |
| Q2 2019 |
$13,264 |
| Q1 2019 |
$13,118 |
| Q4 2018 |
$13,977 |
| Q3 2018 |
$13,298 |
| Q2 2018 |
$13,466 |
| Q1 2018 |
$12,906 |
| Q4 2017 |
$13,703 |
| Q3 2017 |
$13,168 |
| Q2 2017 |
$12,896 |
| Q1 2017 |
$12,779 |
| Q4 2016 |
$13,627 |
| Q3 2016 |
$13,045 |
| Q2 2016 |
$13,147 |
| Q1 2016 |
$13,005 |
| Q4 2015 |
$14,047 |
| Q3 2015 |
$12,087 |
| Q2 2015 |
$11,853 |
| Q1 2015 |
$10,864 |
| Q4 2014 |
$13,118 |
| Q3 2014 |
$12,361 |
| Q2 2014 |
$12,773 |
| Q1 2014 |
$11,353 |
| Q4 2013 |
$13,558 |
| Q3 2013 |
$12,643 |
| Q2 2013 |
$12,973 |
| Q1 2013 |
$12,410 |
| Q4 2012 |
$12,851 |
| Q3 2012 |
$12,953 |
| Q2 2012 |
$13,968 |
| Q1 2012 |
$14,885 |
| Q4 2011 |
$11,439 |
| Q3 2011 |
$16,609 |
| Q2 2011 |
$16,485 |
| Q1 2011 |
$16,502 |
| Q4 2010 |
$15,462 |
| Q3 2010 |
$15,995 |
| Q2 2010 |
$17,132 |
| Q1 2010 |
$16,576 |
| Q4 2009 |
$15,797 |
| Q3 2009 |
$11,621 |
| Q2 2009 |
$10,984 |
| Q1 2009 |
$10,867 |
| Q4 2008 |
$12,346 |
| Q3 2008 |
$11,973 |
| Q2 2008 |
$12,129 |
| Q1 2008 |
$11,848 |
| Q4 2007 |
$12,870 |
| Q3 2007 |
$11,990 |
| Q2 2007 |
$11,084 |
| Q1 2007 |
$12,474 |
| Q4 2006 |
$12,603 |
| Q3 2006 |
$12,280 |
| Q2 2006 |
$11,741 |
| Q1 2006 |
$11,747 |
| Q4 2005 |
$11,599 |
| Q3 2005 |
$11,263 |
| Q2 2005 |
$11,452 |
| Q1 2005 |
$13,091 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$201.220B |
$53.647B |
|
Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer healthcare products. Pfizer's Animal Health business unit discovers, develops and sells products for the prevention and treatment of diseases in livestock and companion animals. It sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, veterinarians, livestock producers, and grocery and convenience stores. Pfizer Inc. is headquartered in New York.
|
